Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsCash from RestructuringChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Accured Expenses (2021 - 2025)

Lyra Therapeutics has reported Change in Accured Expenses over the past 5 years, most recently at -$328000.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at -$328000.0 for Q4 2025, up 42.96% from a year ago — trailing twelve months through Dec 2025 was -$1.8 million (up 69.69% YoY), and the annual figure for FY2025 was -$1.8 million, up 69.69%.
  • Change in Accured Expenses for Q4 2025 was -$328000.0 at Lyra Therapeutics, up from -$942000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for LYRA hit a ceiling of $2.3 million in Q3 2023 and a floor of -$3.3 million in Q2 2024.
  • Median Change in Accured Expenses over the past 5 years was -$144500.0 (2022), compared with a mean of -$13950.0.
  • Biggest five-year swings in Change in Accured Expenses: soared 604.32% in 2022 and later plummeted 2564.37% in 2023.
  • Lyra Therapeutics' Change in Accured Expenses stood at $278000.0 in 2021, then soared by 604.32% to $2.0 million in 2022, then increased by 8.07% to $2.1 million in 2023, then crashed by 127.17% to -$575000.0 in 2024, then surged by 42.96% to -$328000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were -$328000.0 (Q4 2025), -$942000.0 (Q3 2025), and -$202000.0 (Q2 2025) per Business Quant data.